Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 23;102(8):e209268.
doi: 10.1212/WNL.0000000000209268. Epub 2024 Mar 28.

Pathologic Features of Anti-Ku Myositis

Affiliations

Pathologic Features of Anti-Ku Myositis

Munenori Oyama et al. Neurology. .

Abstract

Objective: Characteristics of myositis with anti-Ku antibodies are poorly understood. The purpose of this study was to elucidate the pathologic features of myositis associated with anti-Ku antibodies, compared with immune-mediated necrotizing myopathy (IMNM) with anti-signal recognition particle (SRP) and anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibodies, in muscle biopsy-oriented registration cohorts in Japan and Germany.

Methods: We performed a retrospective pathology review of patients with anti-Ku myositis samples diagnosed in the Japanese and German cohorts. We evaluated histologic features and performed HLA phenotyping.

Results: Fifty biopsied muscle samples in the Japanese cohort and 10 in the German cohort were obtained. After exclusion of myositis-specific autoantibodies or other autoimmune connective tissue diseases, 26 samples (43%) of anti-Ku antibody-positive myositis were analyzed. All the samples shared some common features with IMNM, whereas they showed expression of MHC class II and clusters of perivascular inflammatory cells more frequently than the anti-SRP/HMGCR IMNM samples (71% vs 7%/16%; p < 0.005/<0.005; 64% vs 0%/0%; p < 0.005/<0.005). Anti-Ku myositis biopsies could be divided into 2 subgroups based on the extent of necrosis and regeneration. The group with more abundant necrosis and regeneration showed a higher frequency of MHC class II expression and perivascular inflammatory cell clusters. HLA phenotyping in the 44 available patients showed possible associations of HLA-DRB1*03:01, HLA-DRB1*11:01, and HLA-DQB1*03:01 (p = 0.0045, 0.019, and 0.027; odds ratio [OR] 50.2, 4.6, and 2.8; 95% CI 2.6-2942.1, 1.1-14.5, and 1.0-7.0) in the group with less conspicuous necrosis and regeneration. On the contrary, in the group of more abundant necrosis and regeneration, the allele frequencies of HLA-A*24:02, HLA-B*52:01, HLA-C*12:02, and HLA-DRB1*15:02 were lower than those of healthy controls (p = 0.0036, 0.027, 0.016, and 0.026; OR = 0.27, 0, 0, and 0; 95% CI 0.1-0.7, 0-0.8, 0-0.8, and 0-0.8). However, these HLA associations did not remain significant after statistical correction for multiple testing.

Discussion: While anti-Ku myositis shows necrotizing myopathy features, they can be distinguished from anti-SRP/HMGCR IMNM by their MHC class II expression and clusters of perivascular inflammatory cells. The HLA analyses suggest that anti-Ku myositis may have different subsets associated with myopathologic subgroups.

PubMed Disclaimer

Conflict of interest statement

The authors report no relevant disclosures. Go to Neurology.org/N for full disclosures.

Figures

Figure 1
Figure 1. Study Flow
*Autoantibodies directed against Ku were evaluated by RNA immunoprecipitation and/or line blotting. CTD = connective tissue diseases; MSA = myositis-specific autoantibodies.
Figure 2
Figure 2. Pathologic Features of 2 Subgroups of Myositis With Anti-Ku Antibodies
Bar: 100 µm in HE, MHC class I, MHC class II, MyHCn, and MAC. HE = hematoxylin and eosin; MAC = membrane attack complex (complement C5b-9 complex); MHC = major histocompatibility complex; MyHCn = neonatal myosin heavy chain.

References

    1. Ashton C, Paramalingam S, Stevenson B, Brusch A, Needham M. Idiopathic inflammatory myopathies: a review. Intern Med J. 2021;51(6):845-852. doi:10.1111/imj.15358 - DOI - PubMed
    1. Selva-O’Callaghan A, Pinal-Fernandez I, Trallero-Araguás E, Milisenda JC, Grau-Junyent JM, Mammen AL. Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018;17(9):816-828. doi:10.1016/S1474-4422(18)30254-0 - DOI - PMC - PubMed
    1. Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle Nerve. 2015;51(5):638-656. doi:10.1002/mus.24566 - DOI - PubMed
    1. Uruha A. Autoimmune myositis-Mechanism and therapy development. Neurol Clin Neurosci. 2021;10(6):279-288. doi:10.1111/ncn3.12563 - DOI
    1. Labrador-Horrillo M, Martinez MA, Selva-O'Callaghan A, et al. . Identification of a novel myositis-associated antibody directed against cortactin. Autoimmun Rev. 2014;13(10):1008-1012. doi:10.1016/j.autrev.2014.08.038 - DOI - PubMed